https://scholars.lib.ntu.edu.tw/handle/123456789/568715
標題: | Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin | 作者: | Hsieh C.-J. Kim T.W. Hung C.-F. Juang J. Moniz M. Boyd D.A.K. He L. PEI-JER CHEN CHIEN-HUNG CHEN Wu T.-C. |
公開日期: | 2004 | 出版社: | Elsevier BV | 卷: | 22 | 期: | 29-30 | 起(迄)頁: | 3993-4001 | 來源出版物: | Vaccine | 摘要: | Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy. ? 2004 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984552535&doi=10.1016%2fj.vaccine.2004.03.057&partnerID=40&md5=ad6d16341b7085ee2a5b8a6e3acd0f67 https://scholars.lib.ntu.edu.tw/handle/123456789/568715 |
ISSN: | 0264-410X | DOI: | 10.1016/j.vaccine.2004.03.057 | SDG/關鍵字: | calreticulin; cancer vaccine; CD8 antigen; gamma interferon; tumor antigen; vaccinia vaccine; animal cell; animal experiment; antineoplastic activity; article; controlled study; cytokine release; drug effect; drug efficacy; drug potency; drug targeting; lung tumor; mouse; nonhuman; priority journal; T lymphocyte; Wart virus |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。